Meritz Securities emerging as major investor in biotech industry The brokerage house invests $42 mil in three biotech firms in three months
Translated by Kim So-in 공개 2022-02-11 08:16:06
이 기사는 2022년 02월 11일 08시04분 thebell에 표출된 기사입니다
Meritz Securities is emerging as a big player in the biotech industry, making investments worth billions of won over the last three months.Meritz Securities has made principal investments totaling 50 billion won ($42 million) in three biotech firms - Huinno, ImmuneOncia Therapeutics, and Therabest - from October to December 2021, more than 15 billion won in each firm, according to industry sources said.
Huinno is a healthcare startup developing wearable solutions. Yuhan Corp became the second largest shareholder of the company two years ago. Meritz Securities made a pre-initial public offering (pre-IPO) investment in Huinno in December 2021, valuing the company at 250 billion won. The valuation grew 10 times since Yuhan made its investment. SL Investment, KTB Network, Korea Development Bank, A Ventures, and A1 Ventures also participated in the pre-IPO funding.
ImmuneOncia is a joint venture formed by Yuhan and Nasdaq-listed Sorrento Therapeutics. The company raised 24.5 billion won in a pre-IPO placement in January, which valued the company at about 250 billion won. Meritz Securities, Yuhan, the largest shareholder of ImmuneOncia, Premier Partners, K2 Investment Partners, Shinvestor & Partners, BNH Investment, E& Investment, and Hanyang Securities participated in the funding round.
Therabest develops induced pluripotent stem cell (iPSC)-derived NK cell therapy. Yuhan is also the largest shareholder of the company. Meritz Securities joined a Series C funding round in November 2011, valuing Therabest at 180 billion won. Other investors included DS Asset, DA Value Investment, and Cloud IB Investment.
Meritz Securities’ investments in the biotech companies are led by Kim Jae-kyo, vice president of the brokerage firm’s investment & development division. Kim served as director and head of global strategy division at Yuhan, where he handled mergers and acquisitions and investments in biotech firms at home and abroad.
Meritz Securities plans to make investments with an emphasis on development. It will consider ways to maximize a company's technology and expand its valuation, instead of simply injecting capital.
“We aim to make investments that would open the way for biotech firms with technology to enhance their competitiveness,” said an official at Meritz Securities. “We plan to create a virtuous cycle that promotes trust in K-Bio through investments focusing on development.”(Reporting by Eun-jin Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [i-point]'자가면역질환 신약' 이노보테라퓨틱스, 미국 임상 1상 '성공적'
- [i-point]폴라리스오피스, 엔비디아 ‘커넥트’ 공식 파트너 선정
- [i-point]신성이엔지, 한국종합기술·다스코와 연료전지 발전사업 협약
- [i-point]신테카바이오, 'PEGS 보스턴 2025' 참가
- [AACR 2025]첫 구두발표 진씨커, 경쟁사 넘보는 '유전자가위 액체생검'
- [AACR 2025]이뮨온시아 'CD47' 안전성 굳히기 "경쟁약과 다르다"
- [AACR 2025]항암 신약 항체 대신 '페라틴', 셀레메디 플랫폼 데뷔전
- [AACR 2025]근거 쌓는 '루닛 스코프' 빅파마 공동연구 쇼케이스
- [변곡점 선 콜마비앤에이치]변화의 마지막 카드, 경영진 교체 '강수' 두나
- [변곡점 선 콜마비앤에이치]속절없는 주가 하락 '트리거', 주가 부양 의지 없었나